[Journal of Hepatocellular Carcinoma] Although prognosis is poor for patients with hepatocellular carcinoma (HCC), especially those with cirrhosis, a prolonged subclinical growth period offers a window of time for curative treatment. In this review, researchers discuss the current status of screening, and what can be done to improve its potential.
[Journal of Hepatocellular Carcinoma]
The Breakthrough Therapy designation was based on updated interim results from the multicenter, open-label, phase 1b KEYNOTE-524/Study 116 trial .
[Cancer Management and Research] The aim of this study was to establish a prognostic estimation of CHCs after resection (PECAR) score predicting recurrence on the basis of the clinicopathological data.
Prospective validation shows decrease in predictive ability compared with previous retrospective validations.